SuperworthHalozyme Therapeutics market cap HALO
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $14.3B
- Highest close in our data
- $14.3B
- Oct 2026
Halozyme Therapeutics is worth $14.3B at the close on Oct 23, 2026, at $125.63 a share.
That is up 84% over the last year and up 163% over five years.
Its highest close in our data was $14.3B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $14.3B | $7.3B | $14.3B | +76% |
| 2025 | $8.1B | $6.1B | $9.1B | +32% |
| 2024 | $6.1B | $4.4B | $8.1B | +25% |
| 2023 | $4.9B | $4.2B | $7.5B | −37% |
| 2022 | $7.7B | $4.6B | $8B | +36% |
| 2021 | $5.7B | $4.6B | $6.8B | −2% |
| 2020 | $5.8B | $2.2B | $5.8B | +119% |
| 2019 | $2.6B | $2.1B | $2.8B | +28% |
| 2018 | $2.1B | $2B | $3B | −28% |
| 2017 | $2.9B | $1.5B | $2.9B | +125% |
| 2016 | $1.3B | $965.2M | $1.9B | −42% |
| 2015 | $2.2B | $182.5M | $3.1B | +84% |
| 2014 | $1.2B | $894.1M | $1.9B | −31% |
| 2013 | $1.7B | $583.7M | $1.7B | +132% |
| 2012 | $749.5M | $518.4M | $1.4B | −24% |
| 2011 | $986.1M | $631M | $1B | n/a |
Against its peers
Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| TECHBIO-TECHNE | $11.4B |
| RGENRepligen | $10B |
| KRYSKrystal Biotech | $9.2B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| ONCBeOne Medicines | $42.9B |
| REGNRegeneron Pharmaceuticals | $82.9B |
| Peer median | $19.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Halozyme Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.